Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437032 | 0.80 | MAPT (0.42) | MAPTSMN1; SMN2KMOALDH1A1 | |
| SCHEMBL1437219 | 0.77 | KDM4E (0.36) | MAPTKDRMAPK14TNNI3KSMN1; SMN2 | |
| SCHEMBL10755899 | 0.75 | HTT (0.49) | MAPTLMNAHTTELANEALDH1A1 | |
| SCHEMBL23259898 | 0.71 | ALOX5AP (0.42) | MAPTKDRMAPK14TNNI3KKMO | |
| SCHEMBL31029502 | 0.71 | ALOX5AP (0.41) | MAPTKDRMAPK14TNNI3KSMN1; SMN2 | |
| SCHEMBL9933482 | 0.69 | PDE5A (0.38) | MAPTSMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL3406517 | 0.68 | KMO (0.42) | MAPTKDRMAPK14TNNI3KSMN1; SMN2 | |
| SCHEMBL14920692 | 0.68 | — | — | |
| SCHEMBL31029457 | 0.68 | MAPT (0.41) | MAPTKDRMAPK14TNNI3K | |
| SCHEMBL1457569 | 0.67 | MEN1 (0.47) | MAPTSMN1; SMN2KMOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157482-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157482-A1 | COMPOUNDS AND METHODS | NQO1, CYP1B1, CYP1A1 | MAPT 3800/4885KDR 1355/4885MAPK14 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.